STOCK TITAN

Ionic group discloses Biotricity (BTCY) 3.0M-share beneficial stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Biotricity Inc. shareholder Ionic Ventures and its affiliates report updated beneficial ownership of 3,035,960 shares of common stock. This total includes 443,681 shares of common stock held by Ionic Ventures and up to 2,592,279 shares issuable upon conversion of Series B preferred stock.

The filing explains that further conversions of the preferred stock are limited by a 9.99% beneficial ownership cap in Biotricity’s certificate of designations, which restricts how many conversion shares can be counted. The ownership figures are based on 27,797,711 common shares outstanding as of December 12, 2025, and are jointly reported by Ionic Ventures, Ionic Management, Brendan O’Neil, and Keith Coulston.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6 to Statement on Schedule 13G (this ''Amendment No. 6''), such shares and percentage are based on 27,797,711 shares of the common stock, par value $0.001 per share, of the issuer (the ''Common Stock'') outstanding as of December 12, 2025, as disclosed in the issuer's Registration Statement on Form S-1 (File No. 333-292383), filed by the issuer with the U.S. Securities and Exchange Commission (the ''SEC'') on December 19, 2025 (the ''Registration Statement''). Ownership consists of (i) 443,681 shares of Common Stock held by the reporting person and (ii) an aggregate of up to 2,592,279 shares of Common Stock (the ''Conversion Shares'') issuable upon conversion of shares of Series B Convertible Preferred Stock, par value $0.001 per share, of the issuer (the ''Preferred Stock'') directly held by the reporting person, further conversions of which are subject to a 9.99% beneficial ownership limitation provision (the ''Blocker'') contained in the issuer's Amended Certificate of Designations of the Preferred Stock (the ''Certificate of Designations'').


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 27,797,711 shares of Common Stock outstanding as of December 12, 2025, as disclosed in the Registration Statement. Ownership consists of (i) 443,681 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,592,279 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 27,797,711 shares of Common Stock outstanding as of December 12, 2025, as disclosed in the Registration Statement. Ownership consists of (i) 443,681 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,592,279 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 27,797,711 shares of Common Stock outstanding as of December 12, 2025, as disclosed in the Registration Statement. Ownership consists of (i) 443,681 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,592,279 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G



Ionic Ventures, LLC
Signature:/s/ Ionic Ventures, LLC
Name/Title:Keith Coulston, Manager of Ionic Management, LLC, Manager of Ionic Ventures, LLC
Date:02/04/2026
Ionic Management, LLC
Signature:/s/ Ionic Management, LLC
Name/Title:Keith Coulston, Manager
Date:02/04/2026
Brendan O'Neil
Signature:/s/ Brendan O'Neil
Name/Title:Brendan O'Neil
Date:02/04/2026
Keith Coulston
Signature:/s/ Keith Coulston
Name/Title:Keith Coulston
Date:02/04/2026

Comments accompanying signature: LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated August 8, 2024 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on August 8, 2024).

FAQ

What ownership stake does Ionic Ventures report in Biotricity (BTCY)?

Ionic Ventures and related reporting persons disclose beneficial ownership of 3,035,960 Biotricity common shares. This consists of 443,681 common shares held by Ionic Ventures and up to 2,592,279 shares issuable upon conversion of Series B preferred stock, subject to specified limitations and caps.

How many Biotricity (BTCY) shares are outstanding for this ownership calculation?

The ownership calculation is based on 27,797,711 Biotricity common shares outstanding as of December 12, 2025. This share count comes from Biotricity’s Form S-1 registration statement and is used to determine the reporting group’s percentage ownership of the common stock class.

What preferred stock does Ionic hold in Biotricity (BTCY) and how is it convertible?

Ionic holds 335 shares of Series B convertible preferred stock, which can convert into common shares under defined terms. Up to $2,250,000 of this preferred stock is convertible into up to 7,500,000 common shares at an alternate conversion price of $0.30 per share.

What is the 9.99% beneficial ownership limitation affecting Ionic’s Biotricity (BTCY) position?

Biotricity’s certificate of designations includes a 9.99% beneficial ownership limitation, referred to as the “Blocker.” It prevents Ionic and its affiliates from converting preferred stock into common shares if that conversion would result in beneficial ownership above 9.99% of Biotricity’s outstanding common shares.

How many potential Biotricity (BTCY) conversion shares are not counted as beneficially owned?

The filing states that 4,907,721 conversion shares are not deemed beneficially owned because of the 9.99% Blocker. An additional 3,666,666 conversion shares, tied to $1,100,000 of preferred stock, are excluded due to limits on the number of conversion notices within the relevant period.

Who are the reporting persons in this Biotricity (BTCY) Schedule 13G/A amendment?

The reporting group consists of Ionic Ventures LLC, Ionic Management, LLC, Brendan O’Neil, and Keith Coulston. Ionic Management manages Ionic Ventures, and O’Neil and Coulston, as managers of Ionic Management, share voting and dispositive power over the reported Biotricity shares.
Biotricity Inc

OTC:BTCY

View BTCY Stock Overview

BTCY Rankings

BTCY Latest News

BTCY Latest SEC Filings

BTCY Stock Data

14.29M
17.98M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY